Ocular hypotensive effects of tafluprost and travoprost in normal tension glaucoma; open-label,multi center, cross-over study

UMIN ID: UMIN000001829

Registered date:01/04/2009

Basic Information

• Health condition(s) or Problem(s) studied: Normal Tension Glaucoma
• Date of first enrollment: 2009/04/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Tafluprost or travoprost monotherapy 12 weeks treatment once daily.
Switching monotherapy from travoprost to tafluprost, or from tafluprost to travoprost 12 weeks treatment once daily

Outcome(s)

• Primary Outcome: Intraocular pressure reduction, % reduction of intraocular pressure
• Secondary Outcome: Safety

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1: Patients with exfoliation glaucoma and neovascular glaucoma. 2: Patients with diabetic retinopathy. 3: Patients with advanced visual field loss(MD <-15dB). 4: Excessive myopia (<-6D). 5: Any corneal abnormality or other condition preventing reliable applanation tonometry. 6: Presence of any external disease and inflammation of the eye. 7: History of refractive surgery. 8: History of laser trabeculoplasty, filtering surgery, trabeculotomy, cataract surgery, and other intraocular surgery. 9: Pregnant, pregnant suspect, and nursing woman. Woman who is wishing pregnancy or is not able to prevent pregnancy. 10: The investigator declares any subject ineligible for any sound medical reason.

Related Information

• Primary Sponsor: Mizoguchi Eye Clinic
• Secondary Sponsor: Non
• Source(s) of Monetary Support: Non,Non